A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque
psoriasis and to document the same using sequential photographic images.